Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Given the continued strength of its backlog, we expect that normal cadence of improvement each quarter as we go |
| In closing, 2023 was a strong and transformative year for Labcorp |
| Given the softness that we experienced, especially in the first half of 2023 with the supply constraints that we experienced in the early development in particular, you would expect to see the stronger part of the margin improvement in the first half of the year versus the second, but margins that would still be up year-over-year, even as we go through each quarter of the year and as Adam commented, that we expect margin improvement driven across both of our businesses |
| The 7.1% revenue growth was driven by continued strength in Central Labs, which was up 12%, while early development was down 2% due to higher than normal cancellations |
| What we've faced are some cancellations that are well above normal levels and we expect as we go through 2024 that, that will normalize and get us back to the RFPs and the win rate being positive for us, and therefore providing us with growth |
| The win rate looks good |
| Our win rate looks good |
| Labcorp performed well, driven by strong base business revenue growth in both diagnostics and bioparma |
| Our RFPs look good in both segments |
| Looking forward to 2024, we expect strong enterprise revenue growth of 4.7% to 6.5% |
| We expect margin improvement across both diagnostics and bioparma and we expect a adjusted EPS of $14.30 to $15.40, and applied growth rate at the midpoint of 10% |
| We expect the margins to actually improve across the business, across both diagnostics and biopharma |
| Turning to our enterprise strategy; in the fourth quarter, we continue to see positive momentum from our health systems and regional local lab partnership strategy |
| And we did, in fact, see in the fourth quarter and the full year that esoteric testing volume grew slightly faster than the routine, but it's strong to note that both of them grew strongly and we expect them to continue to both grow strongly, but we would expect esoteric to grow at a slightly higher rate in both volume and the volume obviously is at higher dollars |
| Central Laboratory performed very well in the fourth quarter, and we expect is going to continue to perform well as we look at 5.5% to 7.5% growth in 2024 across the segment |
| And in fact, the EPS range, we've narrowed it versus what that means would have been last year, the year before that, because there is less volatility and then I'd say in the biopharma services business, I would say that the strength we have and momentum is great |
| So I feel good about the guidance that we're providing for each of those businesses |
| So very strong revenue growth |
| The rate in which we integrate the hospital deals will help us and we have very good track record of doing that |
| Our Biopharma laboratory service business, remains a leader in both segments |
| So we feel good about where we are and there's not much risk in the guidance range as we go through this year and the next |
| Fortrea is making very good progress and we would expect to hopefully see those TSAs expire earlier than what we had planned or at least what we had planned for, but again, the costs will go with that |
| We're making good progress |
| For example, we're enabling our central laboratories in China and Geneva to perform liquid biopsy tests for clinical trials and we are well positioned for long-term success in cell and gene therapy and consumerism |
| We see tremendous opportunity for growth as we continue to focus on bringing new innovation, technology and products to market |
| We are comfortable also saying that there'll be margin improvement in each of those businesses |
| Despite the fact that we still have COVID overhang in 2024 versus '23, that we're continuing to improve the margins in our hospital deals, we're expecting to see the margins being accretive and growing this year, which to me is just a good sense of the underlying growth |
| In addition to that, our volume growth is helping us significantly |
| This enabled us to enter 2024 with considerable momentum that we intend to capitalize on to drive further value for our customers, our shareholders and our employees as we pursue our mission to improve health and to improve lives |
| At the same time, there's no doubt that the acceleration of the hospital and local laboratory partnerships has enabled us to grow faster than what we've grown in the past and the good news is we have a strong pipeline of those as we go into the future |
| Statement |
|---|
| Operating loss for the quarter was $123 million due to an impairment charge of $334 million related to our early development research laboratory's business, as we've experienced soft biotech markets |
| While we do not guide the quarterly performance, it's worth noting that first quarter earnings will be below typical quarterly seasonality, due to weather disruption in January that we expect will impact earnings by $0.10 to $0.15 in the quarter |
| The second thing is the funding in smaller biotech has been more difficult |
| That's despite the fact that there is going to be an impact in Diagnostics from weather and we expect it to be $0.10 to $0.15 in the first quarter and, therefore, the first quarter will be the hardest quarter for us of 2024, but the numbers I just gave you and the ranges that I gave you, midpoints, already, we already know what the weather was in January |
| So, we're at kind of a normal level right now, a little bit higher expected than historical and the weather impact that we saw in January, to give you kind of the rounded numbers, probably impacted our revenue by around $25 million and we incrementally, the drop down on that would be at around 60% margin |
| Fully diluted EPS for the quarter was a loss of $1.95 due to the early development impairment charge |
| So you might see the revenue come down for us because the cost is coming down, but it shouldn't have any significant impact |
| One is I think with NHP pricing the way it was, some very small biotech companies that got in line just decided to say we're just not going to do it now and then I also think that there are other pressures with smaller biotech companies that they're going through financially |
| If you look at margin versus prior year, it was down slightly, about 30 basis points |
| We still have a little bit of excess capacity within our early development side of the business |
| So in the fourth quarter, call it around a $6 million headwind that we had due to stranded costs that obviously impact margins |
| The decrease in adjusted operating income and margin was due to lower COVID testing |
| What's happened there is, there's been a lot of cancellations |
| The decrease in adjusted operating income was due to a reduction in COVID testing |
| This includes the favourable impact from foreign currency translation of 60 basis points |
| The reduction in cash flow was due to lower COVID testing |
| We do expect margins to be up in total diagnostics, albeit slightly up because of the impact, to your point, of COVID still being a headwind and the underlying base business margins doing well, but overall, we would say that we're going to be down around $130 million due to COVID |
| So that would have been a real headwind that we're not facing this year |
| From a margin standpoint, call it 20 basis points to 30 basis points of kind of headwind that we're going to get |
| Diagnostics in the fourth quarter was impacted to some degree by the hospital integrations that we're doing, that there were several new ones |
Please consider a small donation if you think this website provides you with relevant information